fenofibric acid has been researched along with Hyperlipidemias in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Berger, JP; Doebber, TW; Forrest, MJ; Jones, AB; Liu, K; Macnaul, KL; Moller, DE; Xu, L; Zhou, G | 1 |
| Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW | 1 |
| Bose, N; Kishan, AU; Modjtahedi, BS; Morse, L; Papakostas, TD; Vavvas, DG | 1 |
| Jacobson, TA | 1 |
| He, XH; Jia, HY; Li, W; Shi, WG; Zhong, BH | 1 |
| Kaushik, M; Mohiuddin, SM; Saurav, A | 1 |
| Drouin, P; Morin, C; Panek, E; Siest, G; Steinmetz, J | 1 |
| Blane, GF; Blümcke, S; Edmondson, NA; Lobeck, H; Prentice, DE; Schwartzkopff, W | 1 |
| Daubresse, JC | 1 |
| Guay, DR | 1 |
| Laredo, C; Torossian, F | 1 |
| Leiss, O; Meyer-Krahmer, K; von Bergmann, K | 1 |
| Filippatos, T; Milionis, HJ | 1 |
5 review(s) available for fenofibric acid and Hyperlipidemias
| Article | Year |
|---|---|
Lipids and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids | 2016 |
Myopathy with statin-fibrate combination therapy: clinical considerations.
Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2009 |
Fenofibric acid for hyperlipidemia.
Topics: Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2012 |
Micronized fenofibrate: a new fibric acid hypolipidemic agent.
Topics: Clinical Trials as Topic; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 1999 |
Treatment of hyperlipidaemia with fenofibrate and related fibrates.
Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
3 trial(s) available for fenofibric acid and Hyperlipidemias
| Article | Year |
|---|---|
Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Copper; Cross-Over Studies; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Oxygen; Postprandial Period; Triglycerides | 2013 |
A comparison of fenofibrate and clofibrate hypolipidemic effects.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Fenofibrate; Humans; Hyperlipidemias; Middle Aged; Propionates; Triglycerides | 1980 |
Cochleovestibular disorders and hyperlipidemia. A controlled trial with fenofibrate.
Topics: Adult; Aged; Clinical Trials as Topic; Cochlea; Double-Blind Method; Female; Fenofibrate; Hearing; Hearing Disorders; Humans; Hyperlipidemias; Hypolipidemic Agents; Labyrinth Diseases; Male; Middle Aged; Propionates; Random Allocation; Vestibule, Labyrinth | 1986 |
6 other study(ies) available for fenofibric acid and Hyperlipidemias
| Article | Year |
|---|---|
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Carrier Proteins; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Type 2; Dogs; Fatty Acid-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isoxazoles; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Propionates; Radioligand Assay; RNA, Messenger; Structure-Activity Relationship; Transcriptional Activation; Triglycerides; Weight Gain | 2005 |
Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents.
Topics: Animals; Carboxylic Acids; Cholesterol; Diabetes Mellitus, Experimental; Fenofibrate; Flavonoids; Hyperlipidemias; Hypolipidemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Models, Molecular; Molecular Structure; Polyethylene Glycols; Resveratrol; Stilbenes; Surface-Active Agents; Triglycerides | 2012 |
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bilirubin; Child; Child, Preschool; Cholesterol; Fenofibrate; gamma-Glutamyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Propionates; Transaminases; Triglycerides; Uric Acid | 1981 |
Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Microbodies; Microscopy, Electron; Middle Aged; Propionates | 1983 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides | 1986 |